Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geraniol SCHEMBL22551423 | 0.73 | KMT2A (0.56) | MAPTLMNATSHRMAPK1RECQL | |
| Citral SCHEMBL7531570 | 0.70 | ALDH1A1 (0.57) | MAPTLMNATSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL15648492 | 0.70 | TSHR (0.54) | MAPTLMNATSHRMAPK1RECQL | |
| SCHEMBL29825691 | 0.70 | CNR2 (0.40) | CNR2 | |
| SCHEMBL20199921 | 0.70 | CYP3A4 (0.35) | CNR2CYP3A4 | |
| SCHEMBL30846026 | 0.70 | CNR2 (0.40) | CNR2 | |
| SCHEMBL20203781 | 0.70 | CYP3A4 (0.35) | CNR2CYP3A4 | |
| SCHEMBL3764971 | 0.70 | LSS (0.34) | CNR2KMT2AMEN1CYP3A4ALOX15 | |
| SCHEMBL28647006 | 0.68 | KMT2A (0.34) | MAPTCNR2KMT2AMEN1CYP3A4 | |
| SCHEMBL26637806 | 0.68 | LSS (0.36) | TSHRCNR2KMT2ALSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243302-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-07-31 | — | — | US | claimed |
| WO-2025129179-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-06-19 | — | — | WO | claimed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | AIP ASSET MANAGEMENT INC. (CA) | 2026-01-22 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250243302-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-07-31 | — | — | US | disclosed |
| WO-2025129179-A1 | FREE RADICAL ETHYLENE/TERPENE COPOLYMERS | BRASKEM S.A. (BR) | 2025-06-19 | — | — | WO | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240108676-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-04-04 | — | — | US | disclosed |
| US-11883454-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230405067-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230346739-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-11-02 | — | — | US | disclosed |
| US-20230293480-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230293555-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-11684604-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220387537-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220054447-A1 | CANNABIS COMPOSITIONS AND METHODS | TETRA BIO-PHARMA INC. (CA) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684604-B2 | Cannabis based therapeutic and method of use | CNR2, CNR1, OPRK1 | MAPT 990/4885LMNA 4763/4885TSHR 4247/4885 |
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | CNR2, CNR1, CCT3 | MAPT 340/4885LMNA 2478/4885TSHR 1333/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | MAPT 719/4885LMNA 293/4885TSHR 4394/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | MAPT 37/4885LMNA 3179/4885TSHR 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.